Suppr超能文献

与新冠肺炎(COVID-19)住院后 30 天内再入院相关的合并症:美国 331136 例患者的回顾性队列研究。

Comorbidities associated with 30-day readmission following index coronavirus disease 2019 (COVID-19) hospitalization: A retrospective cohort study of 331,136 patients in the United States.

机构信息

Department of Epidemiology and Public Health, The University of Maryland School of Medicine, Baltimore, Maryland.

Department of Pathology, The University of Maryland School of Medicine, Baltimore, Maryland.

出版信息

Infect Control Hosp Epidemiol. 2023 Aug;44(8):1325-1333. doi: 10.1017/ice.2022.232. Epub 2022 Oct 3.

Abstract

OBJECTIVE

Hospital readmission is unsettling to patients and caregivers, costly to the healthcare system, and may leave patients at additional risk for hospital-acquired infections and other complications. We evaluated the association between comorbidities present during index coronavirus disease 2019 (COVID-19) hospitalization and the risk of 30-day readmission.

DESIGN, SETTING, AND PARTICIPANTS: We used the Premier Healthcare database to perform a retrospective cohort study of COVID-19 hospitalized patients discharged between April 2020 and March 2021 who were followed for 30 days after discharge to capture readmission to the same hospital.

RESULTS

Among the 331,136 unique patients in the index cohort, 36,827 (11.1%) had at least 1 all-cause readmission within 30 days. Of the readmitted patients, 11,382 (3.4%) were readmitted with COVID-19 as the primary diagnosis. In the multivariable model adjusted for demographics, hospital characteristics, coexisting comorbidities, and COVID-19 severity, each additional comorbidity category was associated with an 18% increase in the odds of all-cause readmission (adjusted odds ratio [aOR], 1.18; 95% confidence interval [CI], 1.17-1.19) and a 10% increase in the odds of readmission with COVID-19 as the primary readmission diagnosis (aOR, 1.10; 95% CI, 1.09-1.11). Lymphoma (aOR, 1.86; 95% CI, 1.58-2.19), renal failure (aOR, 1.32; 95% CI, 1.25-1.40), and chronic lung disease (aOR, 1.29; 95% CI, 1.24-1.34) were most associated with readmission for COVID-19.

CONCLUSIONS

Readmission within 30 days was common among COVID-19 survivors. A better understanding of comorbidities associated with readmission will aid hospital care teams in improving postdischarge care. Additionally, it will assist hospital epidemiologists and quality administrators in planning resources, allocating staff, and managing bed-flow issues to improve patient care and safety.

摘要

目的

患者及其护理人员对住院后再次入院感到不安,这给医疗保健系统带来了沉重的负担,而且患者再次入院后可能会面临医院获得性感染和其他并发症的风险增加。我们评估了在新冠肺炎(COVID-19)住院期间存在的合并症与 30 天内再次入院风险之间的关系。

设计、地点和参与者:我们使用 Premier Healthcare 数据库对 2020 年 4 月至 2021 年 3 月期间出院的 COVID-19 住院患者进行了回顾性队列研究,这些患者在出院后 30 天内被跟踪,以记录是否再次入住同一家医院。

结果

在指数队列的 331136 名独特患者中,有 36827 名(11.1%)在 30 天内至少有 1 次全因再次入院。在再次入院的患者中,有 11382 名(3.4%)因 COVID-19 作为主要诊断再次入院。在调整人口统计学、医院特征、并存合并症和 COVID-19 严重程度的多变量模型中,每增加一个合并症类别,全因再次入院的几率增加 18%(调整后的优势比[aOR],1.18;95%置信区间[CI],1.17-1.19),因 COVID-19 作为主要再入院诊断的几率增加 10%(aOR,1.10;95%CI,1.09-1.11)。淋巴瘤(aOR,1.86;95%CI,1.58-2.19)、肾衰竭(aOR,1.32;95%CI,1.25-1.40)和慢性肺部疾病(aOR,1.29;95%CI,1.24-1.34)与因 COVID-19 再次入院的关联最大。

结论

COVID-19 幸存者在 30 天内再次入院很常见。更好地了解与再入院相关的合并症将有助于医院护理团队改善出院后的护理。此外,这将有助于医院流行病学家和质量管理人员规划资源、分配人员和管理床位流动问题,以改善患者护理和安全。

相似文献

7
Association of Diagnosed Dementia with Post-discharge Mortality and Readmission Among Hospitalized Medicare Beneficiaries.
J Gen Intern Med. 2022 Dec;37(16):4062-4070. doi: 10.1007/s11606-022-07549-7. Epub 2022 Apr 12.
9
The association of acute kidney injury in the critically ill and postdischarge outcomes: a cohort study*.
Crit Care Med. 2015 Feb;43(2):354-64. doi: 10.1097/CCM.0000000000000706.

引用本文的文献

1
Analysis of Clinical Criteria for Discharge Among Patients Hospitalized for COVID-19: Development and Validation of a Risk Prediction Model.
J Gen Intern Med. 2024 Nov;39(14):2649-2661. doi: 10.1007/s11606-024-08856-x. Epub 2024 Jun 27.
2
Rural-urban Differences in Long-term Mortality and Readmission Following COVID-19 Hospitalization, 2020 to 2023.
Open Forum Infect Dis. 2024 Apr 5;11(5):ofae197. doi: 10.1093/ofid/ofae197. eCollection 2024 May.
3
Risk of 30-Day All-Cause Readmission in Interstitial Lung Disease Patients after COVID-19: National-Level Data.
Ann Am Thorac Soc. 2024 Mar;21(3):428-437. doi: 10.1513/AnnalsATS.202305-491OC.

本文引用的文献

3
Preventability of 30-Day Hospital Revisits Following Admission with COVID-19 at an Academic Medical Center.
Jt Comm J Qual Patient Saf. 2021 Nov;47(11):696-703. doi: 10.1016/j.jcjq.2021.08.011. Epub 2021 Aug 24.
4
Antibiotic Use and Bacterial Infection among Inpatients in the First Wave of COVID-19: a Retrospective Cohort Study of 64,691 Patients.
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0134121. doi: 10.1128/AAC.01341-21. Epub 2021 Sep 7.
6
In-Hospital Mortality in a Cohort of Hospitalized Pregnant and Nonpregnant Patients With COVID-19.
Ann Intern Med. 2021 Aug;174(8):1186-1188. doi: 10.7326/M21-0974. Epub 2021 May 11.
8
Real-World Inpatient Use of Medications Repurposed for Coronavirus Disease 2019 in United States Hospitals, March-May 2020.
Open Forum Infect Dis. 2020 Dec 15;8(2):ofaa616. doi: 10.1093/ofid/ofaa616. eCollection 2021 Feb.
9
Risk of Clinical Severity by Age and Race/Ethnicity Among Adults Hospitalized for COVID-19-United States, March-September 2020.
Open Forum Infect Dis. 2020 Dec 28;8(2):ofaa638. doi: 10.1093/ofid/ofaa638. eCollection 2021 Feb.
10
COVID-19 Pandemic: What Have We Learned?
Clin J Oncol Nurs. 2021 Feb 1;25(1):11-12. doi: 10.1188/21.CJON.11-12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验